DAIICHI SANKYO, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 48
- Registration Number
- NCT02647307
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 298
- Registration Number
- NCT02647320
Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 87
- Registration Number
- NCT02633800
- Locations
- 🇫🇷
Hopital Croix-Rousse, Lyon, France
🇵🇱Centrum Onkologii im. Prof. Franciszka Lukaszczyka w Bydgoszczy, Bydgoszcz, Poland
🇧🇪Institut Jules Bordet, Brussels, Belgium
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 106
- Registration Number
- NCT02586233
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
🇺🇸Palmetto Health, USC School of Medicine, Columbia, South Carolina, United States
🇺🇸Chattanooga Center for Neurologic Research, Chattanooga, Tennessee, United States
Multiple Dose Study of D1971a in Healthy Volunteers
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 25
- Registration Number
- NCT02564861
- Locations
- 🇬🇧
Mammersmith Medicines Research Ltd., London, United Kingdom
Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 22
- Registration Number
- NCT02560688
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Study of DS-7080a for the Treatment of Macular Degeneration
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 56
- Registration Number
- NCT02530918
Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 56
- Registration Number
- NCT02496884
A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 18
- Registration Number
- NCT02473627
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 78
- Registration Number
- NCT02452424
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Marin Cancer Care, Greenbrae, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
© Copyright 2024. All Rights Reserved by MedPath